Pharmaceutical Stocks Resist Market Trend, Notch Fourth Consecutive Gain.
Market Bounces Back as Investors Seek Refuge in Defensive Sectors
The Nifty Pharma index gained 1.4% on Monday, 8 June, defying the market selloff, as investors sought refuge in defensive sectors amid heightened global uncertainty, according to experts. The Nifty Pharma index extended its winning streak for a fourth consecutive session on Monday, advancing 1.25%.
Pharma stocks traded mixed on Monday, with several mid- and large-cap names outperforming the broader market despite a sharp selloff in benchmark indices. The Nifty Pharma index remained in the green, supported by gains in select heavyweight stocks.
| Company | Gain/Loss |
|---|---|
| JB Chemicals & Pharmaceuticals | 1.8% |
| Alkem Laboratories | 1.7% |
| Mankind Pharma | 1.7% |
| Torrent Pharmaceuticals | 1.3% |
| Ajanta Pharma | 1.3% |
| Dr Reddy’s Laboratories | 1.3% |
| Gland Pharma | 1.3% |
| Wockhardt | -2.3% |
| Lupin | -0.3% |
| Cipla | -0.5% |
| Piramal Pharma | -0.5% |
| Laurus Labs | -0.8% |
| Divi’s Laboratories | -0.1% |
| Abbott India | -0.1% |
Among the top gainers, JB Chemicals & Pharmaceuticals surged nearly 1.8%, while Alkem Laboratories and Mankind Pharma advanced around 1.7% each. Torrent Pharmaceuticals, Ajanta Pharma, Dr Reddy’s Laboratories, and Gland Pharma also posted gains of up to 1.3%, reflecting continued investor interest in defensive healthcare plays.
On the flip side, Wockhardt emerged as the biggest loser, falling over 2.3%. Lupin, Cipla, Piramal Pharma, and Laurus Labs also traded lower, with declines of 0.3% to 0.8%. Divi’s Laboratories and Abbott India witnessed marginal losses.
The benchmark indices came under pressure, with the Sensex plunging 724.95 points to 73,518.39 and the Nifty 50 falling 222.45 points to 23,138.60 in early trade. The decline was driven by a sharp selloff in global equities, rising crude oil prices and escalating tensions in West Asia.
Market analysts suggest that pharmaceutical stocks generally perform better during times of market instability, as they are viewed as defensive investments. The demand for healthcare remains fairly consistent across economic conditions, making this sector less sensitive to cyclical recessions.
Read also: BPCL, Asian Paints, and Other Crude-Sensitive Stocks Decline Amid Brent Oil Price Surge
Analysts also pointed out that, unlike many sectors whose profits are closely linked to economic expansion, the pharmaceutical sector's performance is frequently bolstered by factors such as medical advancements, product introductions, regulatory approvals, and healthcare demand, allowing it to maintain strength during periods of market pressure.
Investor Takeaway
Investors should consider defensive healthcare plays as a potential safe-haven in times of market uncertainty.
More in Economy
Adani Ports Secures 10-Year Contract for Argentina's First LNG Export Project, Entering South American Market
BPCL, Asian Paints, and Other Crude-Sensitive Stocks Decline Amid Brent Oil Price Surge
India's Growth Prospects Hinge on Swift Reforms for Attracting Investments: Niti Aayog Vice Chairman
